company background image
SLNC.F logo

Silence Therapeutics OTCPK:SLNC.F Stock Report

Last Price

US$9.00

Market Cap

US$1.0b

7D

0%

1Y

260.0%

Updated

27 Mar, 2024

Data

Company Financials +

Silence Therapeutics plc

OTCPK:SLNC.F Stock Report

Market Cap: US$1.0b

SLNC.F Stock Overview

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.

SLNC.F fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Silence Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Silence Therapeutics
Historical stock prices
Current Share PriceUS$9.00
52 Week HighUS$10.90
52 Week LowUS$0.60
Beta1.44
1 Month Change153.52%
3 Month Change500.00%
1 Year Change260.00%
3 Year Change22.45%
5 Year Change1,012.48%
Change since IPO581.82%

Recent News & Updates

Recent updates

Shareholder Returns

SLNC.FUS BiotechsUS Market
7D0%0.9%0.4%
1Y260.0%10.3%28.8%

Return vs Industry: SLNC.F exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: SLNC.F exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is SLNC.F's price volatile compared to industry and market?
SLNC.F volatility
SLNC.F Average Weekly Movementn/a
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: SLNC.F's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine SLNC.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1994109Craig Toomanhttps://www.silence-therapeutics.com

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company’s mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera.

Silence Therapeutics plc Fundamentals Summary

How do Silence Therapeutics's earnings and revenue compare to its market cap?
SLNC.F fundamental statistics
Market capUS$1.00b
Earnings (TTM)-US$54.64m
Revenue (TTM)US$32.05m

31.3x

P/S Ratio

-18.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SLNC.F income statement (TTM)
RevenueUK£25.38m
Cost of RevenueUK£10.32m
Gross ProfitUK£15.06m
Other ExpensesUK£58.32m
Earnings-UK£43.27m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.93
Gross Margin59.34%
Net Profit Margin-170.51%
Debt/Equity Ratio0%

How did SLNC.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.